Neuropathic pain research: an optimistic industry update on recent scientific findings and their potential therapeutic and development implications.
Key Takeaways
- Lanthionine Synthetase C-Like Protein 1 (LanCL1) was identified as a novel neuropathic pain target
- LAT8881 and several Stressed Cell Protectant peptides were shown to act via LanCL1
- In a Phase 1b study, a single intravenous dose of LAT8881 was safe and reduced provoked pain